10-K: HeartSciences Inc. Files Annual Report, Eyes Merger

HeartSciences Inc. filed its annual report for fiscal year 2026, detailing its ongoing development of AI-ECG technology and a proposed merger with Fortitude.

Summary

• HeartSciences Inc. has filed its annual report for the fiscal year ended April 30, 2026.
• The company is focused on advancing electrocardiography (ECG) through AI integration with its MyoVista Insights platform and MyoVista wavECG device.
• A significant version upgrade for MyoVista Insights was released in March 2026, including mobile access and enhanced interoperability.
• The MyoVista wavECG device submission for FDA 510(k) clearance is still under review.
• The company has entered into a merger agreement with Fortitude Mining Holdings, Inc., with the transaction expected to close in the second half of 2026.
• HeartSciences continues to face substantial doubt regarding its ability to continue as a going concern due to recurring losses and limited capital resources.
• The company is seeking additional funding to support operations, product development, and regulatory clearance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the ongoing net losses, substantial doubt about going concern, and the critical need for additional funding, despite positive developments in product launches and a pending merger.

Positives

• MyoVista Insights received Epic Toolbox designation in March 2026, potentially facilitating adoption within Epic-enabled health systems.
• The company launched an AI-ECG Algorithm Marketplace in June 2026, featuring an FDA-cleared AI-ECG model from Bunkerhill Health.
• HeartSciences announced two commercial agreements in May 2026 for the deployment of MyoVista Insights, marking its first mainstream SaaS revenue-generating installations.
• A patent covering machine-learning models for estimating echocardiogram parameters was granted by the European Patent Office in June 2026.

Negatives

• The company has a limited operating history and has incurred significant operating losses since inception, with substantial doubt about its ability to continue as a going concern.
• The MyoVista wavECG device submission to the FDA for 510(k) premarket clearance, submitted in December 2025, remains under review with no assurance of approval.
• HeartSciences has identified material weaknesses in its internal controls over financial reporting.
• The company's stockholders' equity as of April 30, 2026, was approximately $0.2 million, below the Nasdaq minimum requirement of $2.5 million, indicating a risk of delisting.
• The company will require substantial additional funding, which may not be available on acceptable terms.

Risks

• Failure to obtain regulatory clearance or approval for the MyoVista wavECG device and associated AI-ECG algorithms.
• Dependence on third-party manufacturers and suppliers, leading to vulnerability to supply shortages and quality issues.
• Potential delisting from Nasdaq due to failure to meet continued listing requirements, particularly minimum stockholders' equity.
• The proposed merger with Fortitude may not close or may be delayed, adversely affecting the business, financial condition, and stock price.
• The company's ability to secure future funding on acceptable terms is uncertain.
• The evolving FDA regulatory framework for AI and machine learning-enabled medical devices may impose additional requirements and limit algorithm updates.
• The company's reliance on cloud systems, particularly Amazon Web Services, could lead to service disruptions.
• The market price of the company's Common Stock may be highly volatile.

Future Outlook

The company expects to continue incurring significant operating losses and requires substantial additional capital to fund its operations, including R&D, commercialization efforts, and regulatory clearance processes. Future cash needs are expected to be met through debt or equity financing.

Management Comments

• The company's future success depends on its ability to develop, receive regulatory clearance or approval for, and introduce the MyoVista wavECG device and associated AI-ECG algorithms to the market in a timely manner.
• The company believes that enhancing ECG through improved data infrastructure and AI-enabled analysis may support more efficient patient triage and reduce reliance on higher-cost diagnostic procedures.
• The company's management believes that the platform-centric approach, focused on simplifying existing ECG workflows while enabling scalable integration of AI-ECG capabilities, is a key competitive strength.

Industry Context

StockSavvy.ai notes that HeartSciences operates in the rapidly evolving medical device and healthcare IT sector, specifically focusing on AI-driven ECG analysis. The company's strategy to offer a platform for multiple AI-ECG algorithms positions it to capitalize on the growing trend of AI integration in diagnostics, while mitigating the risks associated with developing a single algorithm.

Management Changes

Legal Proceedings

• The company is a party to a certain legal proceeding seeking damages of $180,000, plus prejudgment interest costs and attorney fees, which is in preliminary stages.

Related Party Transactions

• The company has outstanding debt obligations under loan agreements with Front Range Ventures LLC (FRV) and John Q. Adams (JQA), who were shareholders and a director at the time of issuance.
• Warrants were issued to FRV and Mr. Adams as consideration for loan maturity extensions.
• John Q. Adams' note was converted into shares of Common Stock, and his warrants were amended.

Stakeholder Impact

• Shareholders face continued risk of stock price volatility and potential dilution from future equity issuances.
• The going concern opinion and Nasdaq delisting risk could negatively impact investor confidence and the marketability of shares.
• Employees and management may see changes in leadership and roles following the proposed merger.
• Customers (healthcare providers) may benefit from the enhanced MyoVista Insights platform and AI-ECG marketplace, but regulatory approvals for the wavECG device are pending.

Next Steps

• Complete the proposed merger with Fortitude Mining Holdings, Inc.
• Obtain FDA clearance for the MyoVista wavECG device.
• Continue development and commercialization of MyoVista Insights and AI-ECG algorithms.
• Secure additional funding to support operations and growth initiatives.
• Address material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

While the company is making progress in product development and has a pending merger, the significant financial challenges, including recurring losses, substantial doubt about going concern, and material weaknesses in internal controls, warrant a cautious approach. The successful completion of the merger and FDA clearance are critical catalysts for future growth, but the risks remain high.

Keywords

AI-ECG, MyoVista Insights, MyoVista wavECG, FDA clearance, medical device, cardiology, healthcare IT, merger